# US 2015/0031112 A1 · Crystal structure of human alpha-n-acetylglucosaminidase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031112 A1
- Document ID: US20150031112A1
- Status: Published application
- Kind: A1
- Application number: 14/120,882
- Filed: 2014-07-07
- Published: 2015-01-29
- Earliest claimed: 2010-07-22
- Assignees: Shire Human Genetic Therapies, Inc.
- Applicants: Shire Human Genetic Therapies, Inc.
- Inventors: Muthuraman Meiyappan; Michael F. Concino; Angela W. Norton
- Web page: https://patentgrep.com/patent/US20150031112A1

## CPC

- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12Q 1/34: involving hydrolase
- G01N 33/573: for enzymes or isoenzymes
- C12Y 302/0105: Alpha-N-acetylglucosaminidase (3.2.1.50)
- G01N 2333/924: acting on glycosyl compounds (3.2)
- G01N 2500/00: Screening for compounds of potential therapeutic value
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

The present invention provides the three-dimensional structure of human α-N-acetylglucosaminidase (NAGLU) protein. This crystallographic information is useful in the identification and development of novel binding compounds of NAGLU, NAGLU mutants, for example, those associated with Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)), and other NAGLU family members (family 89 α-N-acetylglucosaminidase) which may modulate the activity and/or stability of mutated NAGLU. Such compounds may be useful for the treatment of Sanfilippo syndrome type B (mucopolysaccharidosis III B (MPS III-B)).

## Claims

### Claim at position 1

1-73. (canceled)

### Claim 73

A method of obtaining a purified recombinant NAGLU polypeptide with an altered glycosylation pattern compared to native NAGLU, the method comprising:
a) expressing a recombinant NAGLU polypeptide in a host cell,
b) treating the host cell with a glycosidase inhibitor, and
c) purifying the recombinant NAGLU polypeptide to obtain a purified recombinant NAGLU polypeptide.

### Claim 74 (depends on 73)

The method of claim 73, wherein the glycosidase inhibitor is a mannosidase I inhibitor.

### Claim 75 (depends on 74)

The method of claim 74, wherein the mannosidase I inhibitor is kifunensine.

### Claim 76 (depends on 73)

The method of claim 73, wherein the recombinant NAGLU polypeptide is expressed in mammalian cells.

### Claim 77 (depends on 73)

The method of claim 73, wherein the recombinant NAGLU polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 3.

### Claim 78 (depends on 73)

The method of claim 73, wherein the recombinant NAGLU polypeptide comprises one or more amino acid substitutions, deletions, and/or additions as set forth in Table 4 compared to wild-type human NAGLU polypeptide.

### Claim 79 (depends on 73)

The method of claim 73 further comprising crystallizing the recombinant NAGLU polypeptide.

### Claim 80

(canceled)

### Claim 81 (depends on 73)

The method of claim 73, wherein the recombinant NAGLU polypeptide is a mutant NAGLU.

### Claim 82 (depends on 81)

The method of claim 81, wherein recombinant mutant NAGLU polypeptide is NAGLU-kif.

### Claim at position 12

83-84. (canceled)

### Claim 85 (depends on 79)

The method of claim 79, wherein the crystallized NAGLU is characterized with space group P63 and has unit cell parameters of a=b=205.66 Å, c=78.69 Å, a=b=207.5 Å, c=79.6 Å, or a=b=205.13 Å, c=78.44 Å and bond angles of α=β=90°, γ=120°.

### Claim 86 (depends on 73)

The method of claim 73, wherein the recombinant NAGLU polypeptide comprises an amino acid sequence having at least about 98% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO: 3.

### Claim at position 15

87-89. (canceled)

### Claim 90 (depends on 73)

The method of claim 73, wherein the recombinant NAGLU polypeptide comprises one or more sites of amino acid substitutions, deletions or duplications associated with MPS III-B.

### Claim at position 17

91-93. (canceled)

### Claim 94 (depends on 73)

The method of claim 73, wherein the recombinant NAGLU polypeptide comprises one or more glycans at one or more asparagine (N) residues selected from the group consisting of: N261, N272, N435, N503, N526, and N532 of SEQ ID NO: 3.

### Claim 95 (depends on 94)

The method of claim 94, wherein the one or more glycans comprise at least one N-acetylglucosamine molecule each on N261, N503, N526 and N532, and at least two N-acetylglucosamine molecules each on N272 and N435.

### Claim at position 20

96-102. (canceled)

### Claim 103 (depends on 79)

The method of claim 79, wherein crystallizing the recombinant NAGLU polypeptide further comprises
concentrating the solution of purified recombinant NAGLU polypeptide to a polypeptide concentration at which the NAGLU polypeptide precipitates and forms crystals.

### Claim 104 (depends on 73)

The method of claim 73, wherein the host cell is a mammalian cell.

### Claim 105 (depends on 73)

The method of claim 73, wherein the NAGLU polypeptide is expressed in HT1080 cells.

### Claim at position 24

106-110. (canceled)

### Claim 111 (depends on 73)

The method of claim 73, wherein the NAGLU polypeptide is secreted from the mammalian cells.

### Claim 112

(canceled)

### Claim 113 (depends on 73)

The method of claim 73, wherein purifying the recombinant NAGLU polypeptide comprises using column purification.

### Claim 114

(canceled)

### Claim 115 (depends on 103)

The method of claim 103, wherein the NAGLU polypeptide concentration in solution at which the NAGLU polypeptide precipitates and forms crystals is about 1 mg/ml.

### Claim at position 30

116-133. (canceled)
